Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...

On June 16, 2025, the world lost an incredible and truly one-of-a-kind woman, Susan Elizabeth Boden Bigler, 83. Originally ...

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

The bispecific antibody market is experiencing rapid growth, primarily driven by the increasing prevalence of complex chronic diseases, such as cance ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Market Growth Driven by Increasing Drug Approvals, Advanced Technologies, Rising Chronic Disease Incidence, and Expanding ...